AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03625141
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive vemurafenib 960 mg (four 240 mg tablets) orally (PO) twice daily (BID) on days 1-21 of the run-in period (cycle 1); thereafter, they will receive vemurafenib 720 mg dose (three 240 mg tablets) PO BID on days 22-28 of cycle 1 and on days 1-28 of all subsequent cycles.
Trial: NCT00698035
Drug: Estring
RxNorm normalized name: Estring
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2mg ring inserted vaginally once every 12 weeks
Trial: NCT00111930
Drug: DHEA
RxNorm normalized name: DHEA
DrugBank: Prasterone (DB01708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00110578
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01231607
Drug: 1mg Finasteride active
RxNorm normalized name: finasteride 1 MG
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg finasteride active, by mouth once daily
Trial: NCT01231607
Drug: 0.02mg dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.02mg dutasteride active, by mouth once daily
Trial: NCT01231607
Drug: 0.1mg dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1mg dutasteride active, by mouth once daily
Trial: NCT01231607
Drug: 0.5mg dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg dutasteride active, by mouth once daily
Trial: NCT01231607
Drug: Finasteride placebo
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: finasteride placebo, by mouth once daily
Trial: NCT01231607
Drug: Dutasteride placebo
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dutasteride placebo, by mouth once daily
Trial: NCT03982238
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion therapy for 1 month
Trial: NCT03982238
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month
Trial: NCT03982238
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month
Trial: NCT01010854
Drug: VPA FEC100
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
Trial: NCT01677507
Drug: Variation in eye pressure response to timolol and latanoprost treatment
RxNorm normalized name: latanoprost / timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.
Trial: NCT04172311
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam is a second generation anti-epileptic drug which is broad spectrum and commonly used as add-on in refractory epilepsy
Trial: NCT00861588
Drug: isoflavones (Soylife 25)
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg of soy isoflavones capsule (once daily)
Trial: NCT00340834
Drug: Fingolimod 1.25 mg
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.
Trial: NCT00340834
Drug: Fingolimod 0.5 mg
RxNorm normalized name: fingolimod 0.5 MG
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily.
Trial: NCT00340834
Drug: Interferon β-1a 30 µg
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.~Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.
Trial: NCT02825147
Drug: Pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02825147
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02825147
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02173392
Drug: Brodalumab
RxNorm normalized name: Brodalumab
DrugBank: Brodalumab (DB11776)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brodalumab is a large molecule for the treatment of inflammatory diseases
Trial: NCT01287546
Drug: LY2875358 + erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).
Trial: NCT01287546
Drug: LY2875358 at Part A highest dose
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.
Trial: NCT01287546
Drug: LY2875358 at Part A highest dose + trametinib
RxNorm normalized name: Tramétinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily
Trial: NCT00209170
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.
Trial: NCT02317341
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intravenous dose
Trial: NCT02317341
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intravenous dose given over 40 minutes
Trial: NCT02317341
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously over 40 minutes
Trial: NCT02317341
Drug: Midazolam(placebo)
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously over 40 minutes
Trial: NCT01933256
Drug: HIP2B
RxNorm normalized name: Hydroxyindole-2-carboxylic acid
DrugBank: Indole (DB04532)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00645918
Drug: clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral, 75 mg daily for 6 months starting on day of randomization
Trial: NCT00645918
Drug: clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization
Trial: NCT02538367
Drug: Prucalopride 2mg
RxNorm normalized name: PRUCALOPRIDE 2MG TAB
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00418379
Drug: 300 IR (4M)
RxNorm normalized name: orchard grass pollen extract
DrugBank: Dactylis glomerata pollen (DB10379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IR grass pollen allergen extract tablet starting 4 months before the pollen season
Trial: NCT00418379
Drug: 300 IR (2M)
RxNorm normalized name: orchard grass pollen extract
DrugBank: Dactylis glomerata pollen (DB10379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IR grass pollen allergen extract tablet starting 2 months before the pollen season
Trial: NCT03061045
Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]
DrugBank: Sulfur hexafluoride (DB11104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients enrolled in this study will undergo contrast enhanced ultrasound examination for assessment of brain perfusion.
Trial: NCT02029638
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine at dose 30 mg/m\^2 will be administered daily by intravenous infusion over 30 minutes on Day -6 to Day -2.
Trial: NCT02029638
Drug: diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg diphenhydramine orally prior to antithymocyte globulin infusion.
Trial: NCT02029638
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Days -9 to -7 methylprednisolone 1mg/kg IV 1 hour prior ATG. This dose may be repeated once 3 hours after the first dose of steroids. On Day -6 and -5, methylprednisolone 0.75 mg/kg/ IV as a single dose; on Days -4 and -3, methylprednisolone 0.5 mg/kg/ IV as a single dose; on Day -2 methylprednisolone 0.25 mg/kg/ IV as a single dose.
Trial: NCT02029638
Drug: MESNA
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A series of MESNA doses will be administered for each dose of high dose, post-transplant cyclophosphamide. The total daily dose of MESNA is equal to 80% of the total daily dose of cyclophosphamide.
Trial: NCT02029638
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MMF will be administered at a dose of 15 mg/kg orally three times per day based upon actual body weight, with the maximum of 3 grams a day from Day 5 to 35. The dose will then be reduced to the standard 1 g twice daily thereafter.
Trial: NCT02029638
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone will be administered at a dose of 10 mg orally daily from Day 5 for 12 weeks. Thereafter the dose will be reduced to 5 mg orally daily.
Trial: NCT02029638
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All recipients will receive 5 microgram/kg per day of filgrastim as a single, subcutaneous injection from Day 5 post-transplant until the absolute neutrophil count is greater than 1000/µl on three consecutive measurements over at least 2 days.
Trial: NCT03024840
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane: 1%\~2%
Trial: NCT03024840
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol: 9-15 mg/kg/h
Trial: NCT00691093
Drug: fesoterodine
RxNorm normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment
Trial: NCT00684112
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this arm of the study will receive two identical capsules, containing 300 mg of oral gabapentin each, 1 hour before surgery.
Trial: NCT02600741
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.
Trial: NCT02600741
Drug: Chlorpromazine
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Fluphenazine
RxNorm normalized name: Fluphenazine
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Loxapine
RxNorm normalized name: Loxapine
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Perphenazine
RxNorm normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Pimozide
RxNorm normalized name: Pimozide
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Prochlorperazine
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Thiothixene
RxNorm normalized name: Thiothixene
DrugBank: Thiothixene (DB01623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Thioridazine
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Trifluoperazine
RxNorm normalized name: Trifluoperazine
DrugBank: Trifluoperazine (DB00831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Asenapine
RxNorm normalized name: Asenapine
DrugBank: Asenapine (DB06216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Iloperidone
RxNorm normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT02600741
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Trial: NCT03395223
Drug: Methylene Blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Methylene Blue to treat acquired methaemoglobinaemia
Trial: NCT02335580
Drug: Somatostatin and its analogs
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin and/or octreotide will be intravenously infused.
Trial: NCT03120637
Drug: Methylene Blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00206778
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00206778
Drug: Sodium Valproate
RxNorm normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00553553
Drug: Morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery
Trial: NCT00425477
Drug: bexarotene
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01797991
Drug: Dexamethasone per os
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01797991
Drug: Matching placebo for dexamethasone IV
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01797991
Drug: Dexamethasone IV
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01797991
Drug: Matching placebo for dexamethasone per os
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04198233
Drug: Diazepam
RxNorm normalized name: Diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam 10 mg compounded suppository
Trial: NCT00685529
Drug: Racemic formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 µg of racemic formoterol fumarate BID
Trial: NCT00685529
Drug: Arformoterol tartrate inhalation solution
RxNorm normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 µg of nebulized arformoterol tartrate inhalation solution BID
Trial: NCT00685529
Drug: Racemic formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 24 µg of racemic formoterol fumarate BID
Trial: NCT00776555
Drug: Lisdexamfetamine Dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.